What label best describes this news article?
Mylan once again defends King deal in face of Icahn stock buy PITTSBURGH Mylan Laboratories again reiterated its commitment to the estimated four (B) billion dollar acquisition of brand-name drug maker King Pharmaceuticals despite Wall Street financier Carl Icahn upping his stake in the company. 